Milan 2012 Programme Registration Exhibition Hotels Exhibitor Listing Satellite Meetings Visa Information
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Comparison of outcomes after implantation of iris-claw phakic Artisan lens for treatment of myopia and hyperopia

Poster Details

First Author: J.Keum SOUTH KOREA

Co Author(s):    J. Choi   Y. You   C. Choe   T. Choi     

Abstract Details


To evaluate the efficacy, predictability and safety of implanting iris-claw phakic Artisan lens for treatment of myopia and hyperopia. Comparison of the outcomes between myopic and hyperopic groups implanted with Artisan lens.


Nune Eye Hospital, Seoul, Korea


Thirty-five highly ametropic eyes were included in a comparative retrospective study, i.e. 29 eyes of 16 patients with spherical equivalent of refractive error from -19.75 to -9.0 diopter (D) and 6 eyes of 3 patients with hyperopia ranged from +4.25 to +6.0 D. The dioptric power of the intraocular lens was calculated by considering refraction, keratometry, and anterior chamber depth. We studied pre- and postoperative refractive efficacy, endothelial cell density, complications in two groups, and the mean follow-up period was 24.2 months.


Twenty-four months after surgery, the mean refractive error (SE) was -0.27 D (96.6% of eyes were within +/- 1.00 D of the target refraction) in the myopia group, and +1.12 D (83.3% of eyes were within +/- 1.00 D of the target refraction) in the hyperopia group. The mean uncorrected visual acuity was 0.93, and 0.78, respectively, in both groups at 2 year postoperatively. Mean endothelial cell loss was 6.12% and 9.4% in both groups, respectively, but no statistically significative postoperative endothelial cell loss was found. There were no significant differences regarding the assessed outcome parameters between the two study groups.


Refractive efficacy, predictability and safety after implantation of Artisan lens in both groups were high, however, but the hyperopic group caused slightly more endothelial loss up to 2 years of follow up periods. FINANCIAL DISCLOSURE?: No

Back to previous

loading Please wait while information is loading.